Company Information

  

Address: 5858 HORTON STREET, #455  
City: EMERYVILLE 
State: CA 
Zip Code: 94608 
Telephone: (510) 550-8300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Zogenix, Inc. ("Zogenix" or "we" or "the Company") is a pharmaceutical company developing and commercializing innovative central nervous system ("CNS") therapies for people living with serious and life-threatening rare CNS disorders and medical conditions. Our current primary area of therapeutic focus is rare, or "orphan" childhood-onset epilepsy disorders. We currently own and control worldwide development and commercialization rights to ZX008, our lead Phase 3 product candidate. ZX008 is low-dose fenfluramine for the treatment of seizures associated with two rare and catastrophic forms of childhood-onset epilepsy: Dravet syndrome and Lennox-Gastaut syndrome ("LGS"). Dravet syndrome is a rare form of pediatric-onset epilepsy with life threatening consequences for patients and for which current treatment options are very limited. ZX008 has received orphan drug designation in the United States and the European Union ("the EU") for the treatment of Dravet syndrome.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-4.64NAN/E
12/2017-4.62NAN/E
09/2017-4.40NAN/E
06/2017-3.38NAN/E
03/2017-3.21NAN/E
12/2016-2.77NAN/E
09/2016-2.29NAN/E
06/2016-2.21NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.15Total Liab/Total Assets0.28
Net Inc/Total Assets-0.30Total Liab/Inv Cap0.29
Net Inc/Inv Cap-0.32Total Liab/Comm Equity0.13
Pretax Inc/Net Sales-12.83Interest Coverage Ratio-46.66
Net Inc/Net Sales-12.91Curr Debt/EquityNA
Cash Flow/Net Sales-7.73LTD/EquityNA
SG&A/NetSales5.14Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover1.56Quick Ratio14.52
Inventory Turnover3.04Current Ratio14.52
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.03Inv/Curr AssetsNA
Net Sales/PP&E40.09  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 7.13
Cost of Goods Sold 0.00 0.00 0.00 8.24
Selling & Admin Exps 8.07 20.26 17.05 6.00
Operating Income -31.05 -38.34 -38.43 -22.08
Interest Exp 0.01 0.91 0.58 0.48
Pretax Income -30.18 -39.74 -42.70 -22.47
Other Income 0.88 -0.50 -3.70 0.09
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -30.18 -39.71 -42.79 -23.01

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 271.95 293.50 64.73 65.76
Receivables - Total NA 0.00 0.00 4.68
Inventories - Total NA 0.00 0.00 2.23
Total Current Assets 281.33 304.70 70.73 78.81
Net Property, Plant & Equipment 0.29 0.25 0.22 0.46
Total Assets 391.86 417.61 183.25 190.00
Liabilities        
Accounts Payable 22.58 20.47 20.12 13.98
Debt in Current Liabilities NA 0.00 5.33 6.84
Total Current Liabilities 23.08 20.98 26.09 21.98
Long-Term Debt NA 0.00 13.89 15.76
Total Liabilities 118.09 116.09 123.63 110.52
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.04 0.04 0.03 0.03
Retained Earnings -602.22 -572.04 -532.33 -489.54
Treasury Stock NA NA NA NA
Total Stockholders' Equity 273.77 301.52 59.62 79.48
Total Liabilities and Stockholders' Equity 391.86 417.61 183.25 190.00

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -24.78 -29.44 -20.44 -14.58
Net Cash Provided by Investing Activities -0.07 -0.04 0.00 -0.01
Net Cash Provided by Financing Activities 3.30 258.25 19.41 0.24

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201333.01-80.86--
12/201428.958.59--
12/201527.1826.14-1.94
12/201628.85-69.71-2.77
12/20179.82-126.82-4.62
Growth Rates-26.15----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1817535,826--




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.